Experts call attention to a new turning point in cardiovascular and cerebrovascular diseases

"Atherosclerotic cardiovascular disease (ASCVD) has now become one of the highest mortality rates in China. How to curb the mortality of cardiovascular and cerebrovascular diseases has become the biggest problem faced by society as a whole!" Professor Huo Yong, the First Hospital of Peking University, Professor Wang Yongjun from Beijing Tiantan Hospital, Capital Medical University and Professor Ji Li-nong from Peking University People's Hospital jointly called for the launch of the "STOP ASCVD" vascular health project in China. The whole society should raise awareness of ASCVD, effectively promote integrated management of ASCVD, and fully curb ASCVD. The rising mortality rate eventually promoted the early arrival of the inflection point of cardiovascular and cerebrovascular diseases in China.

Atherosclerotic cardiovascular disease (ASCVD), referred to as dynamic porcine disease, is one of the diseases causing the highest mortality in humans. Coronary heart disease, myocardial infarction, ischemic stroke and other cardiovascular and cerebrovascular diseases belong to the category of ASCVD. Diabetes, hypertension and other diseases are also high risk factors for ASCVD. The population of atherosclerotic cardiovascular disease (ASCVD) is also a high-risk group and a very high-risk group of cardiovascular and cerebrovascular diseases.

In the past ten years, the overall LDL-C compliance rate of cholesterol control in China has increased, but the control of extremely high-risk patients remains poor. The exploration and establishment of an ASCVD integrated management model suitable for the Chinese population will help contain the rising incidence of cardiovascular and cerebrovascular diseases and mortality in China and promote the early turning point of cardiovascular and cerebrovascular disease mortality in China.

Prof. Huo Yong emphasized that in order to solve the most effective intervention and management of moving porridge disease in China, it is necessary to solve the following three problems: First, patients who should be treated without treatment; Second, patients who should be adequately treated without sufficient treatment Treatment; Third, long-term treatment should be long-term treatment of patients without long-term treatment. These three aspects are the shortcomings in the current prevention and control of cardiovascular and cerebrovascular diseases in our country, and they are the first things we must consider to improve and improve.

In addition to patients with coronary heart disease, prevention and treatment of ASCVD in the treatment of stroke and diabetes are equally severe.

In the latest international clinical guidelines, ischemic stroke is included in the ASCVD category of atherosclerotic cardiovascular disease. According to Professor Wang Yongjun, deputy director of the Beijing Tiantan Hospital, stroke disease itself has the characteristics of "high-risk" with high morbidity, high mortality, and high recurrence rate. However, the number of stroke patients in China surpasses 7 million, and the prevalence rate has increased year by year. It has now become the first cause of death for residents in China. According to the report of China in 2012, the total cost of hospitalization for ischemic stroke was as high as 29.845 billion yuan, which brought a heavy burden of disease to our country. The successful experience of stroke prevention and treatment in the United States suggests that: Reducing the burden of stroke and actively triggering statins to control cholesterol are indispensable, but cholesterol control in stroke patients in our country is still not ideal, and there is still a certain gap between Europe and the United States. We must actively take action to regulate Chinese clinicians' management of patients with stroke improves long-term adherence to treatment and curbs the spread of stroke in China.

In addition, diabetic patients are a large potential group of coronary heart disease and stroke, and 65% of diabetic patients die from macrovascular complications such as cardiovascular and cerebrovascular diseases. At present, ASCVD (atherosclerotic cardiovascular disease) is the main cause of death in China, and LDL-C (low-density lipoprotein cholesterol, commonly known as "bad cholesterol") is the primary risk factor for ASCVD. Unfortunately, the awareness, treatment, and control of hypercholesterolemia in patients with diabetes in China are low.

Prof. Ji Li-nung emphasized that statins are the cornerstone for the prevention of ASCVD complications in patients with diabetes, but the current use of statins in diabetic patients is still in need of improvement. Diabetes management can not only focus on blood sugar, must be in line with international standards of management philosophy, to go beyond "blood sugar centering," by strengthening the comprehensive management of multiple risk factors including high cholesterol in order to effectively reduce the complications of diabetes, further Improve the prognosis of diabetic patients.